Skip to content

CoCrMo LOCK Bipolar Femoral Heads FU

A Post-market Study Evaluating Clinical and Safety Outcomes of Bipolar Hemiarthroplasty Using CoCrMo LOCK Bipolar Femoral Heads in Subjects With Hip Fracture

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06885359
Enrollment
60
Registered
2025-03-20
Start date
2026-01-28
Completion date
2028-12-01
Last updated
2026-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Femoral Fractures, Hip Arthropathy

Keywords

Femoral head, Partial Hip Arthroplasty

Brief summary

Study design: monocentric, retrospective, observational and post-market clinical study. Purpose: To demonstrate the safety and performance of CoCrMo LOCK bipolar femoral heads. The eligible study population is represented by the entire population that underwent a hip replacement with CoCrMo LOCK bipolar femoral heads from 1st January 2023 onwards at the site in accordance with the indication for use of the product.

Detailed description

The study is aiming to demoranstrate safety and performance of LOCK Bipolar femoral heads and will do it by considering the rate of revision of any prosthesis component and dislocation, by x-ray evaluation, by patient reported outcomes and walking/residential status. Patients are followed for 2 years after hemiarthroplasty and data are collected at 6 timepoints (pre-operative, intra-operative, at discharge, 4-months follow up, 12 months follow up and 24 months follow up).

Interventions

None listed

Sponsors

Limacorporate S.p.a
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Displaced intracapsular hip fracture (Garden III-IV). * Subjects underwent a Bipolar Hemiarthroplasty with a CoCrMo LOCK Bipolar femoral head as per their Indication For Use from January 1st, 2023, onwards. * No concurrent joint disease at the time of the surgery. * Absence of severe cognitive dysfunction demonstrated by 3 or more correct answers on the Pfeiffer test. * Ability to ambulate independently with or without walking aids before surgery. * Subject willingness to participate.

Exclusion criteria

* Undisplaced or minimally displaced intracapsular hip fracture (Garden I-II). * Any CoCrMo LOCK Bipolar femoral head contraindication for use as reported in the current Instruction For Use. * Pathological fracture secondary to malignant disease. * Subjects with rheumatoid arthritis or symptomatic osteoarthritis. * Previous treatment to the same hip for a fracture at the time of the surgery. * Subjects who were deemed unsuitable for the surgical procedures by the anesthesiologist. * Severe cognitive dysfunction or cognitive impairment demonstrated by 2 or less correct answers on the Pfeiffer test. * Unable to walk before surgery (e.g., wheelchair or bed-ridden subjects).

Design outcomes

Primary

MeasureTime frame
Evaluation of the revision rate of CoCrMo LOCK Bipolar femoral heads at 24 months after surgery.At 24 months after intraoperative visit

Secondary

MeasureTime frameDescription
Evaluation of the dislocation rate (including close reduction) in subjects with CoCrMo LOCK Bipolar femoral heads at 24 months after bipolar hemiarthroplastyAt 24 months after intraoperative visit
Evaluation of the revision incidence of any hip component for any reason at 24 months after bipolar hemiarthroplasty.At 24 months after intraoperative visit
Evaluation of acetabular erosion (according to Baker classification) in subjects with CoCrMo LOCK Bipolar femoral heads at 12 months after Bipolar Hemiarthroplasty.At 12 months after intraoperative visit
Assessment of Harris Hip Score (HHS) at 24 months after Bipolar Hemiarthroplasty with CoCrMo LOCK Bipolar femoral heads.At 24 months after intraoperative visitThe Harris Hip Score goes from 0 to 100, which is the best result.
Assessment of Oxford Hip Score (OHS) completed by subjects with CoCrMo LOCK Bipolar femoral heads at 24 months after Bipolar Hemiarthroplasty.At 24 months after intraoperative visitThe Oxford Hip Score goes from 0 to 48, with 48 being the best outcome
Assessment of Pain Likert-scale in subjects with CoCrMo LOCK Bipolar femoral heads at 24 months after Bipolar Hemiarthroplasty.At 24 months after intraoperative visitThe pain Likert-scale is a 6-point scale: - severe and spontaneous - severe when walking - tollerable - occurs after activity - light intermittent - no pain
Comparison between pre-operative and 4-month walking ability.Performed at preoperative visit and 4months follow up visitFunctional evaluation At the pre-operative time-point, the ability to walk is categorized in: * "able to walk without aids", * "able to walk using one walking aid", * "able to walk using two walking aids", * "able to walk using the walking frame" * "unable to walk" (wheelchair or bed-ridden subjects) At the 4-month post-operative time-point, the ability to walk is investigated is categorized in: * "maintained" (if the subject is able to walk independently as before, with aids if necessary) * "not maintained" (if the subject needs support from another person or uses a wheelchair or is bed-ridden)
Comparison between pre-operative and 4-month residential status.Performed at preoperative visit and 4months follow up visitDaily habit At pre-operative timepoint, subjects are categorized as subjects that before the fracture were used to live: * at their own home (alone or with assistance), * in a sheltered home for independent people, * in a nursing home for people who need assistance with personal care. At 4-month post-operative timepoint, the residential status is categorised in: * maintained (if the subject is living in the same dwelling as before fracture), * not maintained (if the subject moved to a sheltered accommodation or a nursing home)

Countries

Slovenia

Contacts

CONTACTMonica Novello
monica.novello@enovis.com3358162087
CONTACTFrancesca Citossi
clinicalresearch@enovis.com+39 0432 945511

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 8, 2026